News

Apr 10, 2017

BioTelemetry, Inc. to Hold Investor Call on April 10, 2017

BioTelemetry, Inc. (NASDAQ:BEAT) will hold an investor call tomorrow, April 10, 2017 at 9:00am EDT to discuss the recently announced transaction agreement for BioTelemetry to launch a tender offer to acquire LifeWatch AG. The broadcast will be available through the investor information section of the BioTelemetry website: www.gobio.com. If you are unable to participate during […]

Read More
Dec 1, 2016

BioTelemetry, Inc. Announces Acquisition of Telcare’s Remote Diabetes Management Platform

BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, is pleased to announce the acquisition of Telcare Medical Supply, Inc. and associated assets (“Telcare”), increasing the Company’s presence in the large and rapidly growing digital population health management […]

Read More
Mar 25, 2016

BioTelemetry, Inc. Signs Definitive Agreement to Acquire VirtualScopics, Inc.

MALVERN, PA and ROCHESTER, NY – March 25, 2016 – BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, and VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of clinical trial imaging solutions, announced today that the two companies […]

Read More

Publications

Oct 26, 2016

Non-invasive Quantification of Fatty Liver Disease

Jennifer Dolan Fox, Ph.D.; 1 Sep 2015

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatisis (NASH) are emerging as the most prevalent causes of liver disease in Western countries. It is estimated that nearly 6 million Americans have NASH and nearly 600,000 have NASH-related cirrhosis. Download our whitepaper to learn more.

Jun 1, 2016

Exploring Immunotherapies: Beyond Checkpoint Inhibitors

Jennifer Dolan Fox, Ph.D.; 1 Jun 2016

Immunotherapy is an emerging class of cancer treatment, which stimulates the body’s immune system to fight cancer. With the approval of three checkpoint inhibitors (ipilimumab, pembrolizumab and nivolumab) by the Food and Drug Administration (FDA) in the past five years, immunotherapies are seen as exciting treatments able to elicit durable cures. In a previous whitepaper, Immunotherapy – Concept Turned Reality [1], an introduction to the role of the immune system and an overview of checkpoint inhibitors was presented.

Jul 20, 2015

Immunotherapy – Concept Turned Reality

Jennifer Dolan Fox, Ph.D.; 20 Jul 2015

While using the body’s own immune system as a therapeutic approach to fight cancer is not a new concept in oncology, recent successes in clinical studies are making immunotherapy a reality. Immunotherapy represents a paradigm shift. Instead of targeting cancer cells directly like radiation, chemotherapies, and some other targeted therapies, immunotherapy exploits the antitumor capabilities of resident immune cells within the body. The potential for immune checkpoint inhibitors to elicit durable cures has brought new hope to oncology.

May 13, 2015

Blood Pressure Evaluation During Early Phase Trials

Daniel B. Goodman, MD, Michael A. Weber, MD; 3 Nov 2014

More attention is being paid to blood pressure (BP) effects in new chemical entities under development for non-hypertension indications, especially when these are not anticipated and not thoroughly defined during drug development.

Mar 25, 2015

ECHO Inter/Intra-Reader Variability

Goodman DB and Voloshko P; 4 Sep 2014

This report by Daniel B. Goodman, MD, and Polina Voloshko, MD, of BioTelemetry Research, formerly Cardiocore, describes the inter-reader and intra-reader variability in a central reference laboratory for 8 ECHO Cardiogram (ECHO) parameters.

Aug 3, 2014

Effect of Anagrelide on Cardiac Repolarization in Healthy Volunteers: A Randomized, Double-Blind, Placebo- and Positive-Controlled, Thorough QT Study

Troy S et al; 3 Aug 2014
Dec 23, 2013

Loxapine Delivered as a Thermally Generated Aerosol Does Not Prolong QTc in a Thorough QT/QTc Study in Healthy Subjects

Spyker DA, Voloshko P, Heyman ER, Cassella JV; 23 Dec 2013
Jun 5, 2013

Association of Segmental Wall Motion Abnormalities Occurring During Hemodialysis with Post-Dialysis Fatigue

Dubin RF, et al; 5 Jun 2013
Apr 23, 2012

Major Cardiotoxicity Biomarkers During Oncology Development

Voloshko P, McPhillips J; 23 Apr 2012

Webinars

Aug 24, 2016 | 11:00 AM

Advanced Imaging in Oncology

In this free webinar, industry experts Edward Ashton, PhD and Polina Voloshko, MD will discuss the growing range of imaging modalities and analysis methods that are available for use in your clinical trials during oncology drug development.

View Archive

Events

Jun 16, 2017,

Live Lunch & Learn

MassBio
300 Technology Square
Cambridge, MA 02139

Join BTR’s Ed Ashton, Ph.D., VP of Oncology Imaging, and Danielle Lewis, M.S., PMP, Global Operations Account Manager, for an educational lunch & learn entitled, Optimize the Imaging in Clinical Trials by Aligning Operational Excellence and Scientific Expertise. Register Today!

Jun 18-22, 2017

DIA

Chicago, IL
Booth #811

Jun 19-22, 2017

BIO 2017

San Diego, CA
BioTelemetry Research experts will be present and available

Oct 25-26, 2017

OCT Seattle

Seattle, WA
BioTelemetry Research experts will be present and available